🔗 Share this article

The first new treatments for gonorrhoea in decades are being hailed as a "significant breakthrough" in the effort against increasingly resistant strains of the pathogen, according to health experts.

A Global Challenge

Cases of gonorrhoea are escalating globally, with estimates suggesting over 82 million infections each year. Particularly high rates are seen in Africa and countries within the World Health Organization's Western Pacific region, which encompasses Mongolia and China to New Zealand. In England, cases have hit a all-time high, while figures across Europe in 2023 were triple the level compared to those in 2014.

“The clearance of new treatments for gonorrhoea is an important and timely development in the face of growing infection rates, the spread of superbugs and the extremely scarce therapeutic options presently on offer.”

Public health authorities are deeply concerned about the increase in treatment-resistant strains. The global health body has classified it as a "high-priority threat". Recent surveillance showed that resistance to primary antibiotics like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

Recent Treatment Options Secure Authorization

Zoliflodacin, also known as Nuzolvence, was authorized by the US Food and Drug Administration in December for use against gonorrhoea. This disease can lead to significant complications, including the inability to conceive. Experts hope that targeted use of this new drug will help hinder the development of resistance.

Gepotidacin, developed by the pharmaceutical company GlaxoSmithKline, also received approval in concurrent days. This medication, which is employed against UTIs, was proven in research to be effective against drug-resistant strains of the gonorrhoea bacteria.

A Novel Development Model

This new treatment stemmed from a unique collaborative effort for medication research. The charitable organization Global Antibiotic Research & Development Partnership collaborated with the drug firm its industry partner to see it through.

“This milestone represents a major breakthrough in the management of multidrug-resistant gonorrhoea, which up to this point has been staying ahead of our drug pipeline.”

Research Study Data and Global Access

According to results detailed in a major medical journal, zoliflodacin successfully treated more than 90% of genital gonorrhoea infections. This establishes an equal footing with the existing first-line therapy, which combines an injection and a pill. The research involved over 900 patients from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its collaboration, the non-profit has the rights to make available and distribute the drug in many regions with limited resources.

Clinicians directly involved have voiced positive views. Access to a single-dose, oral treatment such as this is hailed as a "game-changer" for gonorrhoea control. This is deemed essential to alleviate the strain of the infection for individuals and to stop the proliferation of highly drug-resistant gonorrhoea worldwide.